Asparaginase in acute lymphoblastic leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue , 2014, Pages S14-S17

  Kawedia, Jitesh D ^a   Rytting, Michael E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Adults; Asparaginase; Pharmacokinetics; Therapeutic drug monitoring; Toxicities

Indexed keywords

ASPARAGINASE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLEEDING; CANCER PATIENT; CANCER SURVIVAL; CHILDHOOD CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MONITORING; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; LEUKEMIA REMISSION; LIVER DYSFUNCTION; PANCREATITIS; THROMBOSIS; TREATMENT OUTCOME; AGE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

AGE FACTORS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; DRUG MONITORING; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

EID: 84925970010     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.06.017     Document Type: Conference Paper

References (55)

1. C.H. Pui, D. Campana, D. Pei, and et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation N Engl J Med 360 2009 2730 2741
2. S.P. Hunger, X. Lu, M. Devidas, and et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group J Clin Oncol 30 2012 1663 1669
3. L.B. Silverman, L. Declerck, R.D. Gelber, and et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995) Leukemia 14 2000 2247 2256
4. C.H. Pui, J.T. Sandlund, D. Pei, and et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital Blood 104 2004 2690 2696
5. C.H. Pui, and W.E. Evans Treatment of acute lymphoblastic leukemia N Engl J Med 354 2006 166 178
6. L.B. Silverman, R.D. Gelber, V.K. Dalton, and et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01 Blood 97 2001 1211 1218
7. P.S. Gaynon, and A.L. Carrel Glucocorticosteroid therapy in childhood acute lymphoblastic leukemia Adv Exp Med Biol 457 1999 593 605
8. L.B. Silverman, T.W. McLean, R.D. Gelber, and et al. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium Cancer 80 1997 2285 2295
9. W. Stock, M. La, B. Sanford, and et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies Blood 112 2008 1646 1654
10. S.E. Sallan, R.D. Gelber, V. Kimball, M. Donnelly, and H.J. Cohen More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials Haematol Blood Transfus 33 1990 459 466
11. S.E. Sallan, S. Hitchcock-Bryan, R. Gelber, J.R. Cassady, E. Frei 3rd, and D.G. Nathan Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia Cancer Res 43 1983 5601 5607
12. M.D. Amylon, J. Shuster, J. Pullen, and et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study Leukemia 13 1999 335 342
13. T.C. Abshire, B.H. Pollock, A.L. Billett, P. Bradley, and G.R. Buchanan Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study Blood 96 2000 1709 1715
14. V.I. Avramis, S. Sencer, A.P. Periclou, and et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study Blood 99 2002 1986 1994
15. B.L. Asselin, D. Ryan, C.N. Frantz, and et al. In vitro and in vivo killing of acute lymphoblastic-leukemia cells by L-asparaginase Cancer Res 49 1989 4363 4368
16. M. Smith, D. Arthur, B. Camitta, and et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia J Clin Oncol 14 1996 18 24
17. M.A. Weiss, and N. Lamanna In adult ALL, less is now more Blood 107 2006 852 853
18. J.M. de Bont, B. Holt, A.W. Dekker, A. van der Does-van den Berg, P. Sonneveld, and R. Pieters Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands Leukemia 18 2004 2032 2035
19. J.M. de Bont, B. van der Holt, A.W. Dekker, A. van der Does-van den Berg, P. Sonneveld, and R. Pieters Adolescents with acute lymphatic leukaemia achieve significantly better results when treated following Dutch paediatric oncology protocols than with adult protocols [in Dutch] Ned Tijdschr Geneeskd 149 2005 400 406
20. A. Testi Difference in outcome of adolescents (14-17 years) with acute lymphoblastic leukemia (ALL) enrolled in the Italian pediatric (AIEOP) and adult (GIMEMA) multicenter protocols J Clin Oncol 24 2006 508s
21. R. Ramanujachar, S. Richards, I. Hann, and et al. Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials Pediatr Blood Cancer 48 2007 254 261
22. E. Barry, D.J. DeAngelo, D. Neuberg, and et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols J Clin Oncol 25 2007 813 819
23. R. Ramanujachar, S. Richards, I. Hann, and D. Webb Adolescents with acute lymphoblastic leukaemia: Emerging from the shadow of paediatric and adult treatment Protocols Pediatr Blood Cancer 47 2006 748 756
24. N. Boissel, M.F. Auclerc, V. Lheritier, and et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials J Clin Oncol 21 2003 774 780
25. D.J. DeAngelo The treatment of adolescents and young adults with acute lymphoblastic leukemia Hematology Am Soc Hematol Educ Program 2005 123 130
26. J.M. Storring, M.D. Minden, S. Kao, and et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen Br J Haematol 146 2009 76 85
27. J. Beck, K. Brandt, M. Brüggemann, and et al. Significant improvement of outcome in adolescents and young adults (AYAs) aged 15-35 years with acute lymphoblastic leukemia (ALL) with a pediatric derived adult ALL protocol; results of 1529 AYAs in 2 consecutive trials of the German Multicenter Study Group For Adult ALL (GMALL) (abstract) Blood 122 2013 839
28. N. Goekbuget, A. Baumann, J. Beck, and et al. PEG-asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for Adult ALL (GMALL) Study 07/2003 Blood 116 2010 219 220
29. A. Advani, M. Earl, A. Bleyer, D. Douer, M. Rytting, and A. Bleyer Toxicities of intravenous (IV) pegasparaginase (ONCASPAR (R)) in adults with acute lymphoblastic leukemia (ALL) (abstract) Blood 110 2007 827a
30. M. Rytting, M. Earl, D. Douer, B. Muriera, A. Advani, and A. Bleyer Toxicities in adults with acute lymphoblastic leukemia (ALL) treated with regimens using pegasparaginase (abstract) Blood 112 2008 672
31. W. Stock, D. Douer, D.J. DeAngelo, and et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel Leuk Lymphoma 52 2011 2237 2253
32. I. Aldoss, M.A. Lunning, V.I. Avramis, and et al. High-grade pegylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles (abstract) Blood 122 2013 2671
33. L.B. Silverman, J.G. Supko, K.E. Stevenson, and et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia Blood 115 2010 1351 1353
34. D. Douer, H. Yampolsky, L.J. Cohen, and et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia Blood 109 2007 2744 2750
35. D.H. Ho, J.P. Whitecar Jr., J.K. Luce, and E. Frei III L-asparagine requirement and the effect of L-asparaginase on the normal and leukemic human bone marrow Cancer Res 30 1970 466 472
36. R.L. Capizzi, J.R. Bertino, R.T. Skeel, and et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies Ann Intern Med 74 1971 893 901
37. C.H. Fu, and K.M. Sakamoto PEG-asparaginase Expert Opin Pharmacother 8 2007 1977 1984
38. C. Domenech, X. Thomas, S. Chabaud, and et al. L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial Br J Haematol 153 2011 58 65
39. A. Pession, M.G. Valsecchi, G. Masera, and et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia J Clin Oncol 23 2005 7161 7167
40. F. Huguet, T. Leguay, E. Raffoux, and et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study J Clin Oncol 27 2009 911 918
41. J.D. Kawedia, C. Liu, D. Pei, and et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia Blood 119 2012 1658 1664
42. M. Rytting Peg-asparaginase for acute lymphoblastic leukemia Expert Opin Biol Ther 10 2010 833 839
43. S.K. Parsons, S.X. Skapek, E.J. Neufeld, and et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia Blood 89 1997 1886 1895
44. D. Killander, A. Dohlwitz, L. Engstedt, and et al. Hypersensitive reactions and antibody-formation during L-asparaginase treatment of children and adults with acute leukemia Cancer 37 1976 220 228
45. W.E. Evans, A. Tsiatis, G. Rivera, and et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma Cancer 49 1982 1378 1383
46. M.H. Woo, L.J. Hak, M.C. Storm, and et al. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia Leukemia 12 1998 1527 1533
47. P.A. Dinndorf, J. Gootenberg, M.H. Cohen, P. Keegan, and R. Pazdur FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL) Oncologist 12 2007 991 998
48. A. Kirkwood, A. Dey, C. Rowntree, and et al. Feasibility of pegylated-asparaginase (PEG-ASP) during induction in adults with acute lymphoblastic leukaemia (ALL): results from the UK phase 3 multicentre trial UKALL 14 (abstract) Blood 122 2013 3900
49. R. Riccardi, J.S. Holcenberg, D.L. Glaubiger, J.H. Wood, and D.G. Poplack L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans Cancer Res 41 1981 4554 4558
50. B.K. Albertsen, H. Schroder, P. Jakobsen, H.J. Muller, N.T. Carlsen, and K. Schmiegelow Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries Br J Clin Pharmacol 52 2001 433 437
51. C. Rizzari, M. Zucchetti, V. Conter, and et al. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure Ann Oncol 11 2000 189 193
52. M. Tsurusawa, M. Chin, A. Iwai, and et al. L-asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment Cancer Chemother Pharmacol 53 2004 204 208
53. M. Wetzler, B.L. Sanford, J. Kurtzberg, and et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511 Blood 109 2007 4164 4167
54. V.I. Avramis, and E.H. Panosyan Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future Clin Pharmacokinet 44 2005 367 393
55. R. Pieters, G. Kaspers, M.D. te Loo, and et al. A prospective study on drug monitoring of pegasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia (abstract) Blood 122 2013 2634